Terremoto Biosciences Raises $108M in Series C Funding

The round also included new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines, as well as existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.

The company plans to use the funds to grow its operations and support research and development.

Terremoto’s main cancer program, TER-2013, is in Phase 1 clinical trials. It is being tested in solid tumors with genetic changes in PIK3CA, AKT, or PTEN, which are found in many cancers, including over half of HR-positive breast cancer cases.

The company is also developing TER-4480 for hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder caused by abnormal blood vessel growth and currently with no approved treatments. TER-4480 is expected to begin clinical trials later this year.

AKT is an important protein that plays a role in the progression of both cancer and hereditary hemorrhagic telangiectasia (HHT). It has three similar forms—AKT1, AKT2, and AKT3. Research shows that AKT1 is the main driver of disease, while AKT2 is often linked to side effects like skin rash and problems with blood sugar control.

Read More:Disney to Lay Off 1,000 Employees Across Company

Many existing drugs targeting the PI3K/AKT pathway have shown limited success because of these side effects, especially those caused by blocking PI3Kα or AKT2. To address this issue, Terremoto has developed a new type of AKT1-selective inhibitor. The goal is to improve treatment effectiveness while reducing side effects and improving overall tolerability.

"The funding will help advance Terremoto’s lead AKT1-selective inhibitor programs into Phase 1 clinical trials for patients with cancer and rare diseases like hereditary hemorrhagic telangiectasia (HHT), said CEO Dr. Charles Baum. He added that the company appreciates the support from both new and existing investors as it works to develop more effective and better-tolerated treatments by targeting AKT1, to address serious unmet medical needs."

About Terremoto Biosciences

Founded by Peter Thompson Terremoto Biosciences is a clinical-stage biotechnology company developing highly targeted small-molecule medicines that are more selective, potent, and effective, thereby improving patient outcomes. It is a private company supported by leading investors and is based in South San Francisco and San Diego, California.

Read More:9 strap Receives $800K Investment Led by Daniel Lubetzky